Negative genetic testing significantly reduced the risk of combined worsening LVEF and evolution to dilated cardiomyopathy in patients with NDLVC (OR 0.1; 95% CI 0.04-0.3; P<0.001).
Cohort (n=432)
Yes
A multiparametric approach integrating clinical, imaging, and genetic data effectively identifies patients with nondilated left ventricular cardiomyopathy at high risk for disease progression.
Effect estimate: OR 0.1 (95% CI 0.04-0.3)
p-value: p=<0.001
BACKGROUND: Nondilated left ventricular cardiomyopathy (NDLVC) is a highly heterogeneous and unexplored category of cardiomyopathies introduced in the 2023 European Society of Cardiology (ESC) guidelines. This study aims to identify factors associated with adverse remodeling in a large multicentre cohort of patients with NDLVC. METHODS: A total of 432 patients with NDLVC (63.4% male, mean age 39.4 ± 14.6 years) with multiparametric characterization were enrolled from January 2010 to May 2023 in 2 high-volume Italian centres. Diagnosis followed ESC criteria. Endpoints were worsening of left ventricular ejection fraction (LVEF) ≥ 10% from the baseline value (or group W), evolution to dilated cardiomyopathy (DCM) (or group E), and the concomitant occurrence of both (or group W + E), assessed at the latest available echocardiographic evaluation. RESULTS: During a median follow-up of 77 months (interquartile range IQR: 48-109), 27.3% of patients experienced worsening LVEF, 28.9% progressed to DCM, and 18.3% reached the combined W + E endpoint. A multivariable model including positive genetic testing associated to myocardial inflammation, family history of cardiomyopathies or sudden cardiac death, intraventricular conduction delay, baseline echocardiographic LVEF < 45%, a ring-like late gadolinium enhancement on cardiac magnetic resonance, and nonsustained ventricular tachycardia at baseline had the strongest discrimination power for predicting worsening LVEF (area under the curve AUC of 0.8; 95% confidence interval CI, 0.75-0.86), evolution to DCM (AUC 0.78; 95% CI, 0.73-0.84) and the combined W + E (AUC 0.84; 95% CI, 0.79-0.89). Negative genetic testing reduced the risk across all the endpoints (odds ratio OR, 0.2; 95% CI, 0.1-0.4; P < 0.001; OR, 0.2; 95% CI, 0.1-0.4; P < 0.001 and OR, 0.1; 95% CI, 0.04-0.3; P < 0.001, respectively). CONCLUSIONS: In this large NDLVC cohort, in which 38% of patients showed an adverse remodelling over long-term follow-up, a multiparametric approach integrating deep phenotyping and genetics effectively identified high-risk patients. CLINICAL TRIAL REGISTRATION: ▪.
Bacigalupi et al. (Mon,) conducted a cohort in Nondilated left ventricular cardiomyopathy (NDLVC) (n=432). Negative genetic testing was evaluated on Combined worsening of LVEF ≥ 10% from baseline and evolution to dilated cardiomyopathy (OR 0.1, 95% CI 0.04-0.3, p=<0.001). Negative genetic testing significantly reduced the risk of combined worsening LVEF and evolution to dilated cardiomyopathy in patients with NDLVC (OR 0.1; 95% CI 0.04-0.3; P<0.001).